Organ transplantation in presensitized recipients continues to be contraindicated for heart and kidney recipients due to the risk of hyperacute rejection, which has no known treatment at this time. We tested whether donor serum, which contains solubie MHC class I antigen, is able to neutralize the effect of antidonor antibody in the recipient and prevent hyperacute or accelerated rejection. A rat model of passive immunization was used to test the role of anti-donor antibody in hyperacute rejection. Seven of 10 recipients of hyperimmune serum (HyS), derived from Lewis rats (ETI 1 ) following 3 ACI (RT1") skin grafts, developed hyperacute or accelerated rejection. intravenous injec* tion of ACI serum prior to the HyS administration prevented hyperacute rejection in all recipients tested. When third-party (Wistar-Furth, RTl tt ) serum was given to Lewis rats injected with HyS, hyperacute rejection was not abrogated. When examining the mechanism of this effect, a simple antibody blocking phenomenon was found to be unlikely since flow cytometry analysis showed that ACI serum needed to be present at >256-fold excess compared to HyS to block anti-ACI antibody binding to RTl.A'-f-cells by 50%. We tested whether the RT1.A* class I antigen in ACI serum had other biologic properties that resulted in the prolonged graft survivah However, removal of RT1.A* antigen from ACI serum prior to use in the passive transfer model did not abrogate the graft Prolongation observed previously. These data suggest that components of donor serum other than MHC class I antigen may be useful for preventing the antibody-mediated component of hy per acute rejection. ® 199-1 Acndemie Frew, Inc.
INTRODUCTION
Renal transplantation in presensitized patients with preformed anti-donor antibody is contraindicated due to the risk of hyperacute or accelerated rejection. No current immunosuppressive modalities are effective in preventing antibody-mediated damage. If a cross-match test prior to human renal transplantation is positive, a different organ recipient must be selected. Currently 40% of the patients awaiting renal transplantation are highly sensitized (>40% panel-reactive antibody) to Potential donors, substantially reducing their chances of receiving a renal transplant. New Solutions to immunotherapy in sensitized patients are urgently needed.
The purpose of this study was to determine whether solubie MHC class I antigen of the donor type has the abiiity to prevent or at least downregulate the immunoJogic injury caused by anti-donor antibody. We therefore chose a rat model in which passive transfer of HyS at the time of cardiac allografting causes hyperacute rejection. Donor serum was used as a source of solubie class I antigen. The reason for using a passive transfer model was to exclude the contribution of the primed cellular immune response.
MATERIALS AND METHODS

Animals
Inbred male ACI rats (RT1°) were donors for skin and cardiac allografts. Male Lewis rats (RTl 1 ) were recipients for all procedures, and Wistar-Furth (WF) rats (RTl u ) were used as third-party controls. All rats weighed between 150 and 200 g and were obtained from Harlan Sprague-Dawley (Indianapolis, IN).
HyS Preparation
Two-centimeter-diameter ACI skin grafts were grafted onto the dorsal neck area of Lewis rats. After the first skin graft was rejected, the second and third ACI skin grafts were subsequently placed at 10-to 14-day intervals. HyS was collected 14-20 days after the third skin graft rejected. Sera from groups of sensitized Lewis rats were combined to make batches of pooled HyS. Batches of HyS were stored at -20°C for later use. (Fig. 2a) . Recipient serum obtained 1 hr after both heart transplantation and injection of 2.0 ml HyS, showed high levels of antidonor antibody (Fig. 2b) . The effect of ACI serum injection on the titer of antiRTl.A* antibody in HyS-injected heart allograft recipients was determined. Transplanted rats injected with HyS serum, as well as ACI serum, did not show a decrease in anti-RTl.A* antibody levels compared to transplanted rats receiving only HyS (Fig. 3a) . Serum collected at the same time point in transplanted rats injected with only ACI serum did not have detectable anti-RTl.A* antibody present. To test whether the solubie RTl.A* in ACI serum is able to effectively reduce the titer of anti-RTl.A* antibody in HyS in vitro, ACI and HyS were mixed at various ratios, and the antibody titer was subsequently determined by flow cytometric analysis (Fig. 3b) . To reduce the MCF exhibited with HyS on LRT7.5 cells by 50%, ACI serum needed to be combined with HyS at a 256:1 ratio, respectively. Lower ratios of ACI to HyS serum reduced the MCF by <20%. To ensure the presence of RTl.A* antigen in ACI serum, an RTl.A*-specific ELISA was performed. Solubie RTl.A* was detectable at a concentration of 195 ± 92 (SD) ng/ ml in normal ACI serum (n -5). Table 1 summarizes the survival times of heterotopic cardiac allografts in naive Lewis rats or rats injected with various combinations of sera. In the control group where no serum injections were performed, ACI hearts rejected at 6-7 days. Injection of 2.5 ml ACI serum alone had no effect on rejection time. Transplanted rats injected with only HyS showed hyperacute or accelerated rejection in 7 of 10 recipients. Administration of ACI serum, prior to HyS, resulted in prolonged graft survival compared to HyS alone in all eight animals tested. To test the specificity of the effect of ACI serum, WF (third-party) serum was injected along with HyS after heart transplantation. The results show that four of seven grafts were rejected in a hyperacute or accelerated manner. Histologie evaluation of hearts rejected early (<4 days), regardless of treatment, showed features typical of humoral rejection with severe tissue edema, hemorrhage, infarction, and polymorphonuclear cell Infiltration (Fig. 4a) . In contrast, hearts rejected at time points > 7 days showed histological evidence of severe lymphocytic inflltration, endothelialitis, and necrosis of myocytes with replacement by flbroblasts (Fig. 4b) .
Detection of Anti
To determine whether solubie MHC class I antigen in donor-type serum has the ability to prevent or downreguiate the immunologic injury caused by anti-donor antibody, ACI serum was depleted of RTl.A 8 antigen by affinity chromatography (Fig. 5 ) prior to injection with HyS. Data from these experiments show that the removal of RTl.A* by this method did not abrogate the ability of ACI serum to prolong graft survival in the passive transfer model (Table 1) .
DISCUSSION
Hyperacute rejection of transplanted organs is believed to be mediated primarily by donor-specific antibody present in the recipient at the time of transplantation. Donor-specific antibody binds to donor histocompatibility antigens, principally MHC class I antigen within the allograft, and initiates a complement-dependent form of rapidly progressive tissue destrucüon 13-5]. It has previously been demonstrated that hyperacute rejection of rat hepatic allografts can be readily produced in recipients presensitized by donor skin when the appropriate inbred strain combinations are used [6] . The ACI to Lewis rat strain combination is a high-responder strain combination. In high-responder models, when three successive skin grafts are performed on the recipient, hyperacute rejection of skin, heart, and liver consistently occurs both in an actively and a passively immunized recipient (4, 7, 8], It has also been shown that immediately following liver transplantation the liver releases significant amounts of solubie MHC class I molecules from the donor liver [9, 10], Infusion of solubie class I antigen derived from liver exträcts has been shown to prolong survival of subsequent cardiac allografts in a donor-specirlc manner in a nonsensitized model [11] . One explanation of the liver's relative resistance to hyperacute rejection compared to other vascularized organ allografts is that the donor-type MHC class I antigen blocks the destructive effects of antidonor antibody, either by neutralizing the antibody or through immunornodulatory effects of immune complexes formed between the donor type MHC class I antigen and donor-specific antibody [11] [12] [13] . However, a precise role of donor MHC class I antigen in conferring resistance to antibody-mediated rejection remains unclear. The goal of the current investigation was to isolate the effects of donor-type MHC class I antigen on antibody-mediated rejection of cardiac allografts using donor serum as a source of MHC class I antigen. The contribution of the sensitized cellular immune response was removed by passively transferring hyperimmune serum to an immunologically naive recipient.
In the present study, hyperacute rejection was prevented in a passive transfer model by injection of donor serum. The inhibition of hyperacute rejection by donor serum occurred despite the fact that the titer of antidonor antibody was unchanged in vivo with injection of ACI serum. Additionally, when HyS and ACI serum were combined in vitro, ACI serum needed to be added in large excess to reduce the anti-RTl.A* antibody titer substantially. Therefore, donor serum used in this manner is not a feasible approach for lowering antibody titers, and our results cannot be explained by a simple antibody-blocking phenomenon.
Donor serum was shown to contain substantial amounts of donor-type MHC class I antigen. The inability of third-party serum to prevent hyperacute rejection suggested that the solubie antigens in the donor serum, principally MHC antigens, may have been responsible for this effect. These results are consistent with the hypothesis that solubie donor MHC class I antigen can inactivate or downregulate antibody-mediated rejection. However, when RT1.A* class I antigen was depleted from ACI serum, the effect on antibody-mediated rejection in the passive transfer model was not abrogated. These results suggest that class I antigen is not the component of donor serum preventing hyperacute rejection, or RTl.A" depletion from ACI serum was not complete. Incomplete depletion of RTl.A a is a possibility since the ELISA is only sensitive to 10 ng/ml. Another explanation is that MHC antigens other than RT1.A (Lewis and ACI strains are a complete MHC mismatch) are involved in this effect.
The Prolongation of graft survival in recipients of hyperimmune serum who do not hyperacutely reject their cardiac allografts could be due to the weli-described phenomenon of antiidiotypic antibody production which prevents acute rejection temporarily [14] [15] [16] . Why some recipients of HyS undergo hyperacute rejection while others have prolonged survival with passive enhancement is unclear. The possibility of inducing hyperacute rejection by administering hyperimmune serum makes this strategy too risky as a means of preventing acute cellular rejection.
The remarkable resistance of the liver to antibodymediated rejection [17, 18] may in part be due to its release of solubie MHC antigens following transplantation. Although our study suggests that serum MHC class I antigen alone plus anti-donor antibody is not solely responsible for preventing hyperacute or accelerated rejection in a passive transfer model, the mechanism of the donor-serum effect in this model Warrants further investigation using more concentrated sources of MHC antigen. Further studies using recombinant MHC antigens are in progress to test its utility in preventing hyperacute or accelerated rejection in sensitized models of organ transplantation.
